SCHEMBL680219

SCHEMBL680219

Cc1ccc(-c2cc3c(cnn3C3CCCCO3)cc2OCc2ccccc2)cn1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
ATR Q13535 1/20 0.42
CYP4F2 P78329 5/20 0.38
CYP4A11 Q02928 5/20 0.38
PTGER1 P34995 2/20 0.38
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
CYP19A1 P11511 2/20 0.37
ADAM17 P78536 1/20 0.37
MAPK1 P28482 1/20 0.36
RIPK2 O43353 1/20 0.35
PDE9A O76083 1/20 0.35
IKBKB O14920 1/20 0.35
LRRK2 Q5S007 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679445 0.90 RXRA (0.50) RXRARXRBRXRGATRCYP4F2
SCHEMBL680337 0.89 RXRA (0.50) RXRARXRBRXRGATRCYP4F2
SCHEMBL680637 0.84 RXRA (0.46) RXRARXRBRXRGATRCYP4F2
SCHEMBL680700 0.82 RXRA (0.52) RXRARXRBRXRGATRCYP4F2
SCHEMBL680099 0.82 RXRA (0.49) RXRARXRBRXRGATRCYP4F2
SCHEMBL680602 0.79 ATR (0.47) RXRARXRBRXRGATRCYP4F2
SCHEMBL21796959 0.79 RXRA (0.45) RXRARXRBRXRGATRCYP4F2
SCHEMBL680965 0.78 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29756252 0.77 RXRA (0.43) RXRARXRBRXRGATRCYP4F2
SCHEMBL20491289 0.77 RXRA (0.43) RXRARXRBRXRGATRCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.